Hofmeister C, Bar N, Martin T, Manteca M, Stefanoni P, Yee A, Ribas P, Santoro A, Hansson M, Rodríguez-Otero P, Thompson E, Kiesel B, Cao C, Chen J, Jeyaraju D, Gaudy A, Hsu K, Petrlik E, Godwin C, Costa L. P-030 Low Infection Rates in Patients (pts) With Relapsed/Refractory Myeloma (RRMM) Treated With Alnuctamab (ALNUC) in a Setting of Infection Reduction Strategies (IRS) and Less Frequent Dosing. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s57-s58. DOI: 10.1016/s2152-2650(24)01933-5.Peer-Reviewed Original Research